Sign In
Buy ARVN
$7.70
-0.300 (-3.75%)
At Close: Jun 03, 2026
Arvinas to Present at Jefferies Global Healthcare Conference
04:01pm, Friday, 29'th May 2026
NEW HAVEN, Conn., May 29, 2026 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today annou
Arvinas Employees Give Back During Company-wide Impact Day
10:30am, Monday, 18'th May 2026
NEW HAVEN, Conn., May 18, 2026 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company working to create a new class of drugs based on targeted protein degradation, to
These Analysts Increase Their Forecasts On Arvinas After Q1 Results
01:54pm, Wednesday, 13'th May 2026
Arvinas Inc (NASDAQ:ARVN) reported downbeat results for the first quarter on Tuesday.
Arvinas, Inc. (ARVN) Q1 2026 Earnings Call Transcript
03:50pm, Tuesday, 12'th May 2026
Arvinas, Inc. (ARVN) Q1 2026 Earnings Call Transcript
Rigel Pharmaceuticals Inks Breast Cancer Drug Deal With Arvinas, Pfizer
02:38pm, Tuesday, 12'th May 2026
Rigel Pharmaceuticals Inc. (NASDAQ:RIGL) stock is trading higher on Tuesday as the company is entering an exclusive global licensing agreement with Arvinas Inc. (NASDAQ:ARVN) and Pfizer Inc. (NYSE:PFE
Arvinas Q1 Earnings Call Highlights
10:10am, Tuesday, 12'th May 2026
Arvinas NASDAQ: ARVN said its first quarter was marked by the FDA approval of VEPPANU, a new licensing agreement with Rigel Pharmaceuticals and continued progress across a clinical-stage pipeline focu
Arvinas, Inc. (ARVN) Reports Q1 Loss, Misses Revenue Estimates
09:31am, Tuesday, 12'th May 2026
Arvinas, Inc. (ARVN) came out with a quarterly loss of $0.9 per share versus the Zacks Consensus Estimate of a loss of $0.95. This compares to earnings of $1.14 per share a year ago.
Rigel strikes licensing deal for Pfizer and Arvinas' breast cancer drug
08:00am, Tuesday, 12'th May 2026
Rigel Pharmaceuticals said on Tuesday it has struck a global licensing deal for Arvinas and Pfizer's recently approved breast cancer drug, marking Rigel's fourth commercial product on the market
Arvinas Reports First Quarter 2026 Financial Results and Provides Corporate Update
07:05am, Tuesday, 12'th May 2026
– First-ever FDA approved PROTAC supports the further development and potential of Arvinas' pipeline – – Announced FDA Approval of VEPPANU ™ (vepdegestrant) for the treatment of ESR1m, ER+/HER
Arvinas and Pfizer Enter into a Transaction with Rigel Pharmaceuticals for the Exclusive Global Rights of VEPPANU (vepdegestrant)
07:00am, Tuesday, 12'th May 2026
– Arvinas and Pfizer to receive $85 million in upfront and transition payments with potential for additional $320 million in development, regulatory, and commercial milestones and tiered royalites o
Arvinas to Report First Quarter 2026 Financial Results on May 12, 2026
07:00am, Tuesday, 05'th May 2026
NEW HAVEN, Conn., May 05, 2026 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a biotechnology company working to create a new class of drugs based on targeted protein degradation, today announced t
PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that the U.S. Food and Drug Administration (FDA) has approved the Guardant
Arvinas Announces FDA Approval of VEPPANU (vepdegestrant) for the Treatment of ESR1m, ER+/HER2- Advanced Breast Cancer
12:43pm, Friday, 01'st May 2026
– VEPPANU™ is the first-and-only FDA-approved PROTAC, a type of heterobifunctional protein degrader – – Approval received in advance of FDA-assigned PDUFA date of June 5, 2026; Arvinas and Pfi
US FDA approves Pfizer, Arvinas' breast cancer drug
12:37pm, Friday, 01'st May 2026
The U.S. Food and Drug Administration on Friday approved Pfizer and Arvinas' drug for a type of breast cancer.
Financial Analysis: Affymax (OTCMKTS:AFFY) versus Arvinas (NASDAQ:ARVN)
04:18am, Friday, 24'th Apr 2026
Affymax (OTCMKTS:AFFY - Get Free Report) and Arvinas (NASDAQ: ARVN - Get Free Report) are both medical companies, but which is the better business? We will contrast the two businesses based on the str
